Comparative Pharmacology
Head-to-head clinical analysis: PHENETRON versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENETRON versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
PHENETRON vs PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
Adults: 50 mg intramuscularly every 6 hours as needed.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
None Documented
None Documented
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic